FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200318682> ?p ?o ?g. }

• W4200318682 endingPage "1152" @default.
• W4200318682 startingPage "1138" @default.
• W4200318682 abstract "To ensure compliance with optimal secondary prevention strategies and document the residual risk of patients following revascularization, we established a postrevascularization clinic for risk-factor optimization at 1 year, with outcomes recorded in a web-based registry. Although coronary revascularization can reduce ischemia, medical treatment of coronary artery disease (CAD) remains the cornerstone of ongoing risk reduction. While standardized referral pathways and protocols for revascularization are prevalent and well studied, post-revascularization care is often less formalized.The University of Ottawa Heart Institute is a tertiary-care center providing coronary revascularization services. From 2015 to 2019, data were prospectively recorded in the CAPITAL revascularization registry, and patient-level procedural, clinical, and outcome data are collected in the year following revascularization. Major adverse cardiovascular event (MACE) was defined as death, myocardial infarction, unplanned revascularization, or cerebrovascular accident. Kaplan-Meier curves were generated to evaluate time-to-event data for clinical outcomes by risk-factor management, and comparisons were performed using log-rank tests and reported by hazard ratio (HR) and 95% confidence intervals (CIs).A cohort of 4147 patients completed 1-year follow-up after revascularization procedure that included 3462 undergoing percutaneous coronary intervention (PCI), 589 undergoing coronary artery bypass graft (CABG), and 96 undergoing both PCI and CABG. In the year following revascularization (median follow-up 13.3 months-interquartile range [IQR]: 11.9-16.5) 11% of patients experienced MACE, with female patients being disproportionately at risk. Moreover, 47.7% of patients had ≥2 risk factors (diabetes, dyslipidemia, overweight, active smoker) at the time of follow-up, with 45.0% of patients with diabetes failing to achieve target hemoglobin (Hb) A1c, 54.8% of smokers continuing to smoke, and 27.1% of patients failing to achieve guideline-directed lipid targets.Patients who have undergone revascularization procedures remain at elevated risk for MACE, and inadequately controlled risk factors are prevalent in follow-up. This highlights the need for aggressive secondary prevention strategies and implementation of programs to optimize postrevascularization care." @default.
• W4200318682 created "2021-12-31" @default.
• W4200318682 creator A5001675402 @default.
• W4200318682 creator A5002193980 @default.
• W4200318682 creator A5004200582 @default.
• W4200318682 creator A5006951158 @default.
• W4200318682 creator A5010412902 @default.
• W4200318682 creator A5011487266 @default.
• W4200318682 creator A5022213227 @default.
• W4200318682 creator A5023039635 @default.
• W4200318682 creator A5026037761 @default.
• W4200318682 creator A5026940390 @default.
• W4200318682 creator A5030129606 @default.
• W4200318682 creator A5033714867 @default.
• W4200318682 creator A5037471440 @default.
• W4200318682 creator A5046193126 @default.
• W4200318682 creator A5049400845 @default.
• W4200318682 creator A5051748961 @default.
• W4200318682 creator A5060041188 @default.
• W4200318682 creator A5061867530 @default.
• W4200318682 creator A5061915282 @default.
• W4200318682 creator A5069748347 @default.
• W4200318682 creator A5083616613 @default.
• W4200318682 creator A5083906814 @default.
• W4200318682 creator A5086188803 @default.
• W4200318682 creator A5086623950 @default.
• W4200318682 creator A5086649080 @default.
• W4200318682 creator A5088056147 @default.
• W4200318682 creator A5088090381 @default.
• W4200318682 date "2021-12-01" @default.
• W4200318682 modified "2023-09-30" @default.
• W4200318682 title "Modifiable Risk Factors and Residual Risk Following Coronary Revascularization" @default.
• W4200318682 cites W1469193822 @default.
• W4200318682 cites W1752045965 @default.
• W4200318682 cites W1980766579 @default.
• W4200318682 cites W1991270018 @default.
• W4200318682 cites W1992000260 @default.
• W4200318682 cites W2000637263 @default.
• W4200318682 cites W2022228654 @default.
• W4200318682 cites W2032510215 @default.
• W4200318682 cites W2037692619 @default.
• W4200318682 cites W2082499401 @default.
• W4200318682 cites W2089468901 @default.
• W4200318682 cites W2107394367 @default.
• W4200318682 cites W2110186675 @default.
• W4200318682 cites W2110424396 @default.
• W4200318682 cites W2115416118 @default.
• W4200318682 cites W2132279603 @default.
• W4200318682 cites W2145007456 @default.
• W4200318682 cites W2155121555 @default.
• W4200318682 cites W2159449551 @default.
• W4200318682 cites W2164089346 @default.
• W4200318682 cites W2168536185 @default.
• W4200318682 cites W2171294019 @default.
• W4200318682 cites W2224950676 @default.
• W4200318682 cites W2289688085 @default.
• W4200318682 cites W2319057797 @default.
• W4200318682 cites W2399652722 @default.
• W4200318682 cites W2402599050 @default.
• W4200318682 cites W2411458668 @default.
• W4200318682 cites W2485118186 @default.
• W4200318682 cites W2517020747 @default.
• W4200318682 cites W2537558475 @default.
• W4200318682 cites W2545173169 @default.
• W4200318682 cites W2549536567 @default.
• W4200318682 cites W2563795256 @default.
• W4200318682 cites W2604920686 @default.
• W4200318682 cites W2611921195 @default.
• W4200318682 cites W2741926355 @default.
• W4200318682 cites W2792181869 @default.
• W4200318682 cites W2899736836 @default.
• W4200318682 cites W2921088856 @default.
• W4200318682 cites W2921388585 @default.
• W4200318682 cites W2922215374 @default.
• W4200318682 cites W2944376050 @default.
• W4200318682 cites W2966780864 @default.
• W4200318682 cites W2970357772 @default.
• W4200318682 cites W2971288779 @default.
• W4200318682 cites W2987736646 @default.
• W4200318682 cites W2997086647 @default.
• W4200318682 cites W3005080544 @default.
• W4200318682 cites W3011371150 @default.
• W4200318682 cites W3020582692 @default.
• W4200318682 cites W3023969949 @default.
• W4200318682 cites W3109883567 @default.
• W4200318682 cites W4206654024 @default.
• W4200318682 cites W4238277289 @default.
• W4200318682 doi "https://doi.org/10.1016/j.mayocpiqo.2021.09.001" @default.
• W4200318682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34934904" @default.
• W4200318682 hasPublicationYear "2021" @default.
• W4200318682 type Work @default.
• W4200318682 citedByCount "4" @default.
• W4200318682 countsByYear W42003186822022 @default.
• W4200318682 countsByYear W42003186822023 @default.
• W4200318682 crossrefType "journal-article" @default.
• W4200318682 hasAuthorship W4200318682A5001675402 @default.
• W4200318682 hasAuthorship W4200318682A5002193980 @default.
• W4200318682 hasAuthorship W4200318682A5004200582 @default.

• next